Loading...
Market
Eli Lilly's AI-driven antimicrobial project gets clinical trial approval by end of 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA or other relevant regulatory bodies
Story
Eli Lilly ($LLY) Collaborates with OpenAI to Develop Medicines for Drug-Resistant Bacteria
Jun 25, 2024, 02:04 PM
Eli Lilly ($LLY) has announced a collaboration with OpenAI to leverage generative AI in the discovery of novel medicines aimed at treating drug-resistant bacteria. This partnership aims to accelerate the development of new antimicrobials to combat antimicrobial resistance (AMR), which is considered one of the top public health threats globally. Dave Ricks, CEO of Eli Lilly, emphasized that this collaboration is a significant step forward in the fight against antimicrobial resistance, combining the expertise of Lilly's scientists with OpenAI’s advanced AI platform. Diogo Rau, EVP & chief information and digital officer at Lilly, stated that generative AI opens new opportunities for custom, purpose-built technologies in this battle. The initiative also supports Lilly's earlier commitment to addressing drug-resistant pathogens through its Social Impact Venture Capital Portfolio, which includes the AMR Action Fund.
View original story
Similar markets
Yes • 50%
No • 50%
Yes, identified and announced • 33%
Yes, identified but not announced • 33%
No, not identified • 33%
Yes • 50%
No • 50%
0-1 projects • 25%
2-3 projects • 25%
4-5 projects • 25%
More than 5 projects • 25%
Machine Learning • 25%
Deep Learning • 25%
Natural Language Processing • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
1-3 strains • 33%
4-6 strains • 33%
More than 6 strains • 33%
Yes • 50%
No • 50%
Drug Discovery • 25%
Patient Care • 25%
Operational Efficiency • 25%
Regulatory Compliance • 25%